📰 Eric Ando News
Eric Ando News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Ando. Real-time updates on events, politics, business and more.
July 7, 2024
we should point out nbc news has not yet verified that reporting half what we do have this afternoon is new reaction from a spokesperson for mark meadows. joining me now, luke broad january broadwater, matt miller, and joyce vance. luke, who exactly could be picking up these legal fees for at least it seems a dozen witnesses testifying before the january 6th committee? >> well, there are two funds that are funding witnesses lawyers. one is the save america pac which is run directly con...
June 1, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
May 10, 2022
RLS-0071 is ReAlta's lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic ischemic encephalopathy, severe asthma, and other rare diseases ReAlta
April 14, 2022
Evox Therapeutics Appoints Peter Jones as Vice President of CMC - read this article along with other careers information, tips and advice on BioSpace
April 14, 2022
Investegate announcements from EVOX THERAPEUTICS LIMITED, Evox Therapeutics Appoints Peter Jones as Vice President of CMC
April 14, 2022
OXFORD, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, announces the appointment of Peter Jones as Vice President
May 28, 2021
Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine - read this article along with other careers information, tips and advice on BioSpace
May 27, 2021
SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral...
February 17, 2021
Published: Feb 17, 2021 SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc. (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-10...